Synthesis and ex vivo profiling of chemically modified cytomegalovirus CMVpp65 epitopes

Journal of Peptide Science

Volumn 14, Issue 3, 2008, Pages 313-320

  Jones, Matthew A ^a   Notta, Jatinder K ^a   Cobbold, Mark ^a   Palendira, Mainthan ^a   Hislop, Andrew D ^a   Wilkie, John ^a   Snaith, John S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Chemically modified peptide epitopes; Cytomegalovirus CMVpp65 epitope; Hydrophobic amino acids; Synthetic antigens

Indexed keywords

AMINO ACID; CYCLOHEXYLALANINE; CYCLOHEXYLGLYCINE; CYCLOLEUCINE; CYTOMEGALOVIRUS ANTIGEN PP65; HLA A ANTIGEN; LEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEO PENTYLGLYCINE; TERT BUTYLGLYCINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SUBSTITUTION; AMINO ACID SYNTHESIS; ARTICLE; BINDING AFFINITY; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOASSAY; LYMPHOCYTE ACTIVATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN STRUCTURE;

ANTIGENS, VIRAL; CYTOMEGALOVIRUS; EPITOPES; PHOSPHOPROTEINS; VIRAL MATRIX PROTEINS;

CYTOMEGALOVIRUS;

EID: 40749127992     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.930     Document Type: Article

References (38)

1. Alford CA, Stagno, S, Pass RF, Britt WJ. Congenital and perinatal cytomegalovirus infections. Rev. Infect. Dis. 1990: 12: S745-S753.
2. Plotkin SA. Vaccination against cytomegalovirus, the changeling demon. Pediatr. Infect. Dis. J. 1999; 18: 313-326.
3. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell-surface expression of human cytomegalovirus (HCMV) GP55-116 (GB)-use of HCMV-recombinant vaccina virus-infected cells in analysis of the human neutralizing antibody-response. J. Virol. 1990; 64: 1079-1085.
4. Adler SP, Shaw KV, McCoy M, Burke RL, Liu H. Guinea-pig and human cytomegalovirus do not share cross-reactive neutralizing epitopes. J. Med. Virol. 1995; 47: 48-51.
5. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 1992; 326: 663-667.
6. Riddell SR, Greenberg PD. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev. Med. Virol. 1997; 7: 181-192.
7. Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 1995; 171: 26-32.
8. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 2001; 1: 209-219.
9. La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R. Diamond DJ. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 2002; 100: 3681-3689.
10. Akiyama Y, Maruyama K, Mochizuki T, Sasaki K, Takaue Y, Yamaguchi K. Identification of HIA-A24-restrieted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus. Immunol. Lett. 2002; 83: 21-30.
11. Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JGP. Human cytomegalovirus-specific cytotoxic T-cells - relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein-B expressed by recombinant vaccina viruses. J. Exp. Med. 1988; 168: 919-931.
12. Kern F, Bunde T, Faulhaber N, Kiecker F, Khatamzas E, Rudawski IM, Pruss A, Gratama JW, Volkmer-Engert R, Ewert R Reinke P, Volk HD, Picker LJ. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 2002; 185: 1709-1716.
13. Berzofsky JA. Epitope selection and design of synthetic vaccines-molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines. Ann. N.Y. Acad. Sci. 1993; 690: 256-264.
14. Guichard G, Zerbib A, Le Gal F-A, Hoebeke J, Connan F, Choppin J, Briand J-P, Guillet J-G. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: Implications for recognition by tumor-infiltrating lymphocytes. J. Med. Chem. 2000; 43: 3803-3808.
15. Pogue RR, Eron J, Frelinger JA, Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus POL peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. U.S.A. 1995; 92: 8166-8170.
16. Sarobe P, Pendleton CD, Akatsuka T, Lau D, Engelhard VH, Feinstone SM, Berzofsky JA. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Invest. 1998; 102: 1239-1248.
17. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 1996; 157: 2539-2548.
18. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA. Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998; 4: 321-327.
19. Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs - first listing. Immunogenetics 1995; 41: 178-228.
20. Ruppert J, Sidney J, Cells E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74: 929-937.
21. Van Bleek GM, Nathenson SG. Isolation of an endogenously processed immunodominant viral peptide from the class-I H-2KB molecule. Nature 1990; 348: 213-216.
22. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes - a comparison of the conformations of 5 viral peptides presented by HLA-A2. Cell 1993; 75: 693-708.
23. Rognan D, Scapozza L, Folkers G, Daser A. Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human-leukocyte antigen. Proc. Natl. Acad. Sci. U.S.A. 1995; 92: 753-757.
24. Geistlinger TR, Guy RK. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J. Am. Chem. Soc. 2003; 125: 6852-6853.
25. 3)COOH into biologically active decapeptides: a study on C/Si/Ge bioisosterism. J. Organomet. Chem. 2001; 628: 183-194.
26. Bain JD, Wacker DA, Kuo EE, Chamberlin AR. Site-specific incorporation of nonnatural residues into peptides - effect of residue structure on suppression and translation efficiencies. Tetrahedron 1991; 47: 2389-2400.
27. Jackson DY, Quan C, Artis DR, Rawson T, Blackburn B, Struble M, Fitzgerald G, Chan K, Mullins S, Burnier JP, Fairbrother WJ, Clark K, Berisini M, Chui H, Renz M, Jones S, Fong S. Potent α-4 β-1 peptide antagonists as potential anti-inflammatory agents. J. Med. Chem. 1997; 40: 3359-3368.
28. Chang WC, White PD. Fmoc Solid Phase Peptide Synthesis. Oxford University Press: Oxford, UK, 2000; 42.
29. Chang WC, White PD. Fmoc Solid Phase Peptide Synthesis. Oxford University Press: Oxford, UK, 2000; 62-63.
30. Khan N, Best D, Bruton R. Nayak L, Rickinson AB, Moss PAH. T-cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J. Immunol. 2007; 178: 4455-4465.
31. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, DeBolt S, Ferguson D, Seibel G, Kollman P. AMBER, A package of computer-programs for applying molecular mechanics, normal-mode analysis, molecular-dynamics and free-energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Commun. 1995; 91: 1-41.
32. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A 2nd generation force-field for the simulation of proteins, nucleic-acids, and organic-molecules. J. Am. Chem. Soc. 1995; 117: 5179-5197.
33. InsightII, Accelrys, 10188 Telesis Court, Suite100, San Diego, CA 9212, USA.
34. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV. The cytotoxic T-lymphocyte response to multiple hepatitis-B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 1995; 181: 1047-1058.
35. Robbins PA, Garboczi DN, Strominger JL. HLA-A*0201 complexes with 2 10-mer peptides differing at the P2-anchor residue have distinct refolding kinetics. J. Immunol. 1995; 154: 703-709.
36. Venkatraman J, Shankaramma SC, Balaram P. Design of folded peptides. Chem. Rev. 2001; 101: 3131-3152.
37. Czerkinsky C, Anderson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O. Reverse elispot assay for clonal analysis of cytokine production. I. Enumeration of γ-interferon-secreting cells. J. Immunol. Methods 1988: 110: 29-36.
38. Garcia KC, Teyton L, Wilson IA. Structural basis of T cell recognition. Annu. Rev. Immunol. 1999; 17: 369-397.